Spots Global Cancer Trial Database for metastatic gastric adenocarcinoma

Every month we try and update this database with for metastatic gastric adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma	NCT03071042	Metastatic Gast...	Apatinib Docetaxel	18 Years -	Sir Run Run Shaw Hospital
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	NCT05555251	HER2-positive B... HER2-positive G... HER2-positive M... Metastatic Gast... Metastatic Gast...	BI-1607 BI-1607 Trastuzumab	18 Years -	BioInvent International AB
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer	NCT02314117	Metastatic Gast... Gastroesophagea...	Ramucirumab Capecitabine Cisplatin Placebo Fluorouracil	18 Years -	Eli Lilly and Company
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma	NCT02539225	Metastatic Gast... Gastroesophagea...	Ramucirumab Placebo S-1 Oxaliplatin Paclitaxel	20 Years -	Eli Lilly and Company
A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma	NCT03071042	Metastatic Gast...	Apatinib Docetaxel	18 Years -	Sir Run Run Shaw Hospital
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	NCT06203600	Advanced Esopha... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Ga... Unresectable Ga...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Nivolumab Paclitaxel Questionnaire A... Ramucirumab	18 Years -	National Cancer Institute (NCI)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread	NCT06324357	Metastatic Brea... Metastatic Gast... Gastroesophagea... Esophageal Aden...	Zongertinib Trastuzumab der... Trastuzumab emt...	18 Years -	Boehringer Ingelheim
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer	NCT06251973	Metastatic Esop... Advanced Unrese... Metastatic Gast... Metastatic Gast... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Es... Unresectable Ga... Unresectable Ga... Unresectable Ga...	AgenT-797 Botensilimab Balstilimab Ramucirumab Paclitaxel	18 Years -	Memorial Sloan Kettering Cancer Center
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer	NCT05342389	Metastatic Gast... Metastatic Gast...	Camrelizumab Apatinib Mesyla...	18 Years - 75 Years	Sixth Affiliated Hospital, Sun Yat-sen University
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	NCT05555251	HER2-positive B... HER2-positive G... HER2-positive M... Metastatic Gast... Metastatic Gast...	BI-1607 BI-1607 Trastuzumab	18 Years -	BioInvent International AB
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body	NCT04248452	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Esop... Metastatic Gast... Oligometastatic... Oligometastatic... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Capecitabine Fluorouracil Leucovorin Leucovorin Calc... Oxaliplatin Radiation Thera...	18 Years -	Eastern Cooperative Oncology Group
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	NCT03641313	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Unresectable Ga... Unresectable Ga...	Berzosertib Computed Tomogr... Endoscopic Biop... Irinotecan Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	NCT05041153	Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Unresectable Ga...	Lenvatinib Pembrolizumab	18 Years -	M.D. Anderson Cancer Center
MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C	NCT02391038	Advanced Gastro... Gastroesophagea... Recurrent Gastr... Recurrent Gastr... Metastatic Gast... Metastatic Gast... Recurrent Gastr...	MLN0264	18 Years -	Takeda
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer	NCT04220827	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Peritoneal Carc... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant...	Paclitaxel	18 Years -	M.D. Anderson Cancer Center
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer	NCT05342389	Metastatic Gast... Metastatic Gast...	Camrelizumab Apatinib Mesyla...	18 Years - 75 Years	Sixth Affiliated Hospital, Sun Yat-sen University
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer	NCT03918499	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Recurrent Gastr... Recurrent Gastr...	Cyclophosphamid... Cytokine-based ... Pembrolizumab	18 Years -	City of Hope Medical Center
MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C	NCT02391038	Advanced Gastro... Gastroesophagea... Recurrent Gastr... Recurrent Gastr... Metastatic Gast... Metastatic Gast... Recurrent Gastr...	MLN0264	18 Years -	Takeda
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma	NCT02539225	Metastatic Gast... Gastroesophagea...	Ramucirumab Placebo S-1 Oxaliplatin Paclitaxel	20 Years -	Eli Lilly and Company
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	NCT04660760	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant...	Paclitaxel Quality-of-Life... Ramucirumab Trifluridine an...	18 Years -	Academic and Community Cancer Research United

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: